Tìm theo
Fluticasone Propionate
Các tên gọi khác (6 ) :
  • Cutivate
  • Fluticason
  • Fluticasona
  • Fluticasone
  • Fluticasone propionate
  • Fluticasonum
Thuốc Gốc
Small Molecule
CAS: 80474-14-2
ATC: D07AC17, R01AD08, R03BA05
ĐG : Apotex Inc. , http://www.apotex.com
CTHH: C25H31F3O5S
PTK: 500.571
Fluticasone propionate, a medium-potency synthetic corticosteroid, is used topically to relieve inflammatory and pruritic symptoms of dermatoses and psoriasis, intranasally to manage symptoms of allergic and non-allergic rhinitis, and orally for the treatment of asthma. Fluticasone proprionate is marketed under several different brand names such as Flonase®. Fluticasone propionate is also available as a combination product of azelastine hydrochloride and fluticasone propionate called Dymista™. Dymista™ is indicated in patients over 12 years old for symptomatic relief of seasonal allergic rhinitis.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C25H31F3O5S
Phân tử khối
500.571
Monoisotopic mass
500.184429407
InChI
InChI=1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,19+,22+,23+,24+,25+/m1/s1
InChI Key
InChIKey=WMWTYOKRWGGJOA-CENSZEJFSA-N
IUPAC Name
(1R,2S,8S,10S,11S,13R,14R,15S,17S)-1,8-difluoro-14-{[(fluoromethyl)sulfanyl]carbonyl}-17-hydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-14-yl propanoate
Traditional IUPAC Name
fluticasone propionate
SMILES
[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
Độ tan chảy
272-273 °C
Độ hòa tan
0.51 mg/L (insoluble)
logP
3.4
logS
-4.6
pKa (strongest acidic)
13.56
pKa (Strongest Basic)
-3.4
PSA
80.67 Å2
Refractivity
121.65 m3·mol-1
Polarizability
49.26 Å3
Rotatable Bond Count
6
H Bond Acceptor Count
4
H Bond Donor Count
1
Physiological Charge
0
Number of Rings
4
Bioavailability
1
MDDR-Like Rule
true
Dược Lực Học : Fluticasone is an extremely potent vasoconstrictor and anti-inflammatory agent. Its effectiveness in inhaled forms is due to its direct local effect.
Cơ Chế Tác Dụng : Fluticasone propionate, a medium-potency synthetic corticosteroid, is used topically to relieve inflammatory and pruritic symptoms of dermatoses and psoriasis, intranasally to manage symptoms of allergic and non-allergic rhinitis, and orally for the treatment of asthma. Fluticasone proprionate is marketed under several different brand names such as Flonase®. Fluticasone propionate is also available as a combination product of azelastine hydrochloride and fluticasone propionate called Dymista™. Dymista™ is indicated in patients over 12 years old for symptomatic relief of seasonal allergic rhinitis. Binds to the glucocorticoid receptor. Unbound corticosteroids cross the membranes of cells such as mast cells and eosinophils, binding with high affinity to glucocorticoid receptors (GR). The results include alteration of transcription and protein synthesis, a decreased release of leukocytic acid hydrolases, reduction in fibroblast proliferation, prevention of macrophage accumulation at inflamed sites, reduction of collagen deposition, interference with leukocyte adhesion to the capillary wall, reduction of capillary membrane permeability and subsequent edema, reduction of complement components, inhibition of histamine and kinin release, and interference with the formation of scar tissue. In the management of asthma, the glucocorticoid receptor complexes down-regulates proinflammatory mediators such as interleukin-(IL)-1, 3, and 5, and up-regulates anti-inflammatory mediators such as IkappaB [inhibitory molecule for nuclear factor kappaB1], IL-10, and IL-12. The antiinflammatory actions of corticosteroids are also thought to involve inhibition of cytosolic phospholipase A2 (through activation of lipocortin-1 (annexin)) which controls the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
Dược Động Học :
▧ Absorption :
The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Bioavailability, intranasal = <2%; Oral bioavailability is negligible and the major circulating entity is an inactive metabolite.
▧ Volume of Distribution :
IV administration = 4.2 L/kg
▧ Protein binding :
91%
▧ Metabolism :
Fluticasone propionate is metabolized in the liver by cytochrome P450 3A4-mediated hydrolysis of the 5-fluoromethyl carbothioate grouping. This transformation occurs in 1 metabolic step to produce the inactive 17-(beta)-carboxylic acid metabolite, the only known metabolite detected in man.
▧ Route of Elimination :
Less than 5% of the oral dose was excreted in the urine as metabolites. The rest of the dose is excreted in the feces and parent drug and metabolites.
▧ Half Life :
Terminal elimination half-life = 7.8 hours
▧ Clearance :
The total blood clearance of fluticasone propionate is high (average, 1,093 mL/min), with renal clearance accounting for less than 0.02% of the total.
Chỉ Định : Fluticasone propionate, a medium-potency synthetic corticosteroid, is used topically to relieve inflammatory and pruritic symptoms of dermatoses and psoriasis, intranasally to manage symptoms of allergic and non-allergic rhinitis, and orally for the maintenance treatment of asthma as prophylactic therapy and for patients requiring oral corticosteroid therapy for asthma.
Tương Tác Thuốc :
  • Conivaptan CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation). Concurrent use of orally inhaled fluticasone with strong CYP3A4 inhibitors is not recommended.
  • Crizotinib Concurrent use with crizotinib may prolong QTc interval. Consider alternative therapy.
  • Telithromycin Telithromycin may reduce clearance of Fluticasone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Fluticasone if Telithromycin is initiated, discontinued or dose changed.
  • Tipranavir Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Fluticasone propionate. Concomitant therapy should be avoided if possible.
  • Voriconazole Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of fluticasone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of fluticasone if voriconazole is initiated, discontinued or dose changed.
Liều Lượng & Cách Dùng : Aerosol, metered - Respiratory (inhalation)
Cream - Topical
Powder - Respiratory (inhalation)
Spray, metered - Nasal
Spray, metered - Nasal - DYMISTA : 0.137MCG /SPRAY; 0.05MCG/SPRAY (AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE)
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
  • Công ty : GlaxoSmithKline
    Sản phẩm biệt dược : Cutivate
  • Công ty : Intas
    Sản phẩm biệt dược : Ezicas
  • Công ty : GlaxoSmithKline
    Sản phẩm biệt dược : Flixonase
  • Công ty : GlaxoSmithKline
    Sản phẩm biệt dược : Flixotide
  • Công ty : GlaxoSmithKline
    Sản phẩm biệt dược : Flonase
  • Công ty : GlaxoSmithKline
    Sản phẩm biệt dược : Flovent
  • Công ty : GlaxoSmithKline
    Sản phẩm biệt dược : Flovent HFA
  • Công ty :
    Sản phẩm biệt dược : FLOVENTHFA
  • Công ty : GlaxoSmithKline
    Sản phẩm biệt dược : Flunase
  • Công ty : Teva
    Sản phẩm biệt dược : Nasofan
  • Công ty : GlaxoSmithKline
    Sản phẩm biệt dược : Pirinase
  • Công ty : GlaxoSmithKline
    Sản phẩm biệt dược : Seretide
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00588
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D01708
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0462-0333-15
PharmGKB
http://www.pharmgkb.org/drug/PA449686
Wikipedia
http://en.wikipedia.org/wiki/Fluticasone_propionate
RxList
http://www.rxlist.com/cgi/generic2/cutivate.htm
Drugs.com
http://www.drugs.com/cdi/fluticasone-furoate-spray.html
... loading
... loading